New narcolepsy drug enters first human safety tests

NCT ID NCT07613710

Recruiting now Symptom relief Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affects absorption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu AH69593
What this could lead to: If successful, this could point toward a new treatment option to help manage narcolepsy symptoms.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

CRST, Clinical Research Services Turku
COMPLETED

Turku, 20520, Finland
Terveystalo Helsinki, Sleep Clinic
RECRUITING

Helsinki, 00380, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.